BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is based in Modi'in, Israel.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone972-2548-9100
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/28/2019 (Confirmed)
OptionableNot Optionable
BIOLINERX LTD/S (NASDAQ:BLRX) Frequently Asked Questions
What is BIOLINERX LTD/S's stock symbol?
BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX."
How were BIOLINERX LTD/S's earnings last quarter?
BIOLINERX LTD/S (NASDAQ:BLRX) posted its earnings results on Thursday, August, 11th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the Zacks' consensus estimate of ($0.07). View BIOLINERX LTD/S's Earnings History.
When is BIOLINERX LTD/S's next earnings date?
What price target have analysts set for BLRX?
3 brokers have issued 1 year price targets for BIOLINERX LTD/S's shares. Their forecasts range from $2.00 to $4.00. On average, they anticipate BIOLINERX LTD/S's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 571.0% from the stock's current price. View Analyst Price Targets for BIOLINERX LTD/S.
What is the consensus analysts' recommendation for BIOLINERX LTD/S?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLINERX LTD/S.
What are Wall Street analysts saying about BIOLINERX LTD/S stock?
Here are some recent quotes from research analysts about BIOLINERX LTD/S stock:
- 1. According to Zacks Investment Research, "Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases. " (11/14/2018)
- 2. Maxim Group analysts commented, "BioLineRx reported 3Q18 with a net loss of ($6.2M) and ended the quarter with $35M in cash on the balance sheet. We estimate a runway to late 2019." (11/8/2018)
- 3. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $4 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, BL-8040. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (7/30/2018)
Has BIOLINERX LTD/S been receiving favorable news coverage?
News coverage about BLRX stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIOLINERX LTD/S earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term.
Are investors shorting BIOLINERX LTD/S?
BIOLINERX LTD/S saw a drop in short interest during the month of February. As of February 28th, there was short interest totalling 714,355 shares, a drop of 38.1% from the February 15th total of 1,154,627 shares. Based on an average daily trading volume, of 1,256,708 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.5% of the company's shares are sold short. View BIOLINERX LTD/S's Current Options Chain.
Who are some of BIOLINERX LTD/S's key competitors?
Some companies that are related to BIOLINERX LTD/S include VBI Vaccines (VBIV), Galmed Pharmaceuticals (GLMD), REDHILL BIOPHAR/S (RDHL), TAIWAN LIPOSOME/S (TLC), Aratana Therapeutics (PETX), Paratek Pharmaceuticals (PRTK), Millendo Therapeutics (MLND), BELLUS Health (BLUSF), Menlo Therapeutics (MNLO), resTORbio (TORC), Cue Biopharma (CUE), Ocular Therapeutix (OCUL), Nature's Sunshine Products (NATR), Aquestive Therapeutics (AQST) and Axovant Sciences (AXON).
What other stocks do shareholders of BIOLINERX LTD/S own?
Who are BIOLINERX LTD/S's key executives?
BIOLINERX LTD/S's management team includes the folowing people:
- Mr. Philip A. Serlin CPA, MBA, Chief Exec. Officer (Age 59)
- Ms. Mali Zeevi CPA, Chief Financial Officer (Age 43)
- Dr. Ella Sorani, VP R&D (Age 51)
- Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 44)
- Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 67)
Who are BIOLINERX LTD/S's major shareholders?
BIOLINERX LTD/S's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include ETF Managers Group LLC (0.35%), Menta Capital LLC (0.07%) and Two Sigma Securities LLC (0.05%).
Which institutional investors are buying BIOLINERX LTD/S stock?
BLRX stock was acquired by a variety of institutional investors in the last quarter, including ETF Managers Group LLC, Menta Capital LLC and Two Sigma Securities LLC.
How do I buy shares of BIOLINERX LTD/S?
Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BIOLINERX LTD/S's stock price today?
One share of BLRX stock can currently be purchased for approximately $0.4471.
How big of a company is BIOLINERX LTD/S?
BIOLINERX LTD/S has a market capitalization of $47.61 million. The biotechnology company earns $-24,350,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis.
What is BIOLINERX LTD/S's official website?
How can I contact BIOLINERX LTD/S?
BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]
MarketBeat Community Rating for BIOLINERX LTD/S (NASDAQ BLRX)
MarketBeat's community ratings are surveys of what our community members think about BIOLINERX LTD/S and other stocks. Vote "Outperform" if you believe BLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
